{"task_id": "112e445c91ed4fb2", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 256/464)", "text": "Infections and Sexually Transmitted Infections\n245\n\n--- Page 267 ---\nSEXUALLY TRANSMITTED INFECTIONS (STIS)\n(CONT\u2019D)\n\u0002\nSECONDARY SYPHILIS\ndevelops within 2 weeks\nto 6 months, with symptoms such as fever,\nmaculopapular rash, mucocutaneous lesions,\nalopecia, lymphadenopathy, meningitis, uveitis,\nand cranial neuritis\n\u0002\nTERTIARY SYPHILIS\ndevelops after year(s) and\nmay involve the heart (aortitis), eyes (iritis,\nArgyll Robertson pupil), bones/soft tissues\n(gummas), and neurologic system (general\nparesis, a rapidly progressive dementia with\npsychotic features and tabes dorsalis which\nSEXUALLY TRANSMITTED INFECTIONS (STIS)\n(CONT\u2019D)\naffects posterior columns of the spinal cord and\nthe dorsal roots, leading to pain episodes,\ndecreased vibration and proprioception, absent\nreflexes, and bowel/bladder dysfunction)\n\u0002\nDIAGNOSIS\nfirst line diagnostic test of choice for a\nprimary syphilitic chancre should be either DFA or\nPCR, if available. Otherwise, treponemal serologies\nare more sensitive and become positive earlier\nthan non treponemal serologies and would be\npreferred if primary syphilis is a consideration\nDiagnostic Method\nTest(s)\nUtility\nDirect visualization\nDark field\nmicroscopy\nTraditional but availability is limited\nVisualization with fluorescent Ab\nDFA\nDiagnosis of 18 syphilis\nSensitive/specific\nMolecular testing\nPCR\nDiagnosis of 18 syphilis. Most sensitive/specific\nbut not readily available\nTreponemal serology (presence of Ab\nagainst TP)\nFTA ABS\nTPPA\nMHA TP\nTP EIA\nINNO LIA\nDiagnosis of syphilis\nSensitive; however, does not differentiate\nvenereal from non venereal treponematosis\nNon treponemal serology (presence\nof Ab against cardiolipin/lecithin)\nVDRL\nRPR\nScreening\nRPR titer helpful in staging\nCheck for reinfection\nTreatment monitoring\nAbbreviations: DFA, direct fluorescent antibody; EIA, enzyme immunoassay; FTA ABS, fluorescent treponemal\nantibody absorption; MHA TP, microhemagglutination assay for antibody to TP; PCR, polymerase chain\nreaction; RPR, rapid plasma reagin test; TP, treponema pallidum; TPPA, TP particle agglutination assay;\nVDRL, Venereal Disease Research Laboratory; INNO LIA, line immunoassay\n\u0002\nTREATMENTS\nfor primary, secondary and early\nlatent (<1 year) syphilis, benzathine penicillin G\n2.4 M units IM \u00051 (preferred) or doxycycline\n100 mg PO BID \u00052 weeks. For late latent\n(>1 year) syphilis, gummatous and cardiovascular\nsyphilis, benzathine penicillin G 2.4 M units IM\nq7days \u00053 weeks. For neurosyphilis or syphilitic\neye disease, give benzathine penicillin G 3 4 M\nunits q4h IV \u000510 14 days. Follow up is essential.\nTreatment failure is defined as persistent symptoms\nor failure of serologic test to decline by 4 fold within\n6 months\nJAMA 2003 290:11\nPELVIC INFLAMMATORY DISEASE\n\u0002\nPATHOPHYSIOLOGY\nincludes endometritis, tubo o\nvarian abscess, salpingitis, and pelvic peritonitis.\nMost commonly due to N. gonorrhoeae, C. tracho\nmatis, M. hominis, U. urealyticum; may involve\nSEXUALLY TRANSMITTED INFECTIONS (STIS)\n(CONT\u2019D)\nendogenous (gut) organisms including anaerobes.\nComplications include infertility, ectopic preg\nnancy, and chronic pelvic pain\n\u0002\nCLINICAL FEATURES\nlower abdominal pain, abnor\nmal vaginal bleeding/discharge, and dyspareunia\nmay be mild and non specific. Findings include\nlower abdominal tenderness, adnexal tenderness,\nand cervical motion tenderness\n\u0002\nDIAGNOSIS\nhigh index of clinical suspicion. Cervi\ncal swab and urine NAAT for Chlamydia and gonor\nrhea. Ultrasound. Pregnancy test\n\u0002\nTREATMENTS\noutpatients (ceftriaxone 250 mg IM\n\u00051 and doxycycline 100 mg PO BID \u000514 days, or\nlevofloxacin 500 mg PO daily \u000514 days); add\nmetronidazole 500 mg PO BID \u000514 days if there\nare risk factors for anaerobic pathogens. Inpati\nents (doxycycline 100 mg PO q12h and cefoxitin\n2 g IV q6h \u000514 days, or clindamycin 900 mg IV q8h\nand gentamicin 1.5 mg/kg IV q8h \u000514 days)\nSEXUALLY TRANSMITTED INFECTIONS (STIS)\n(CONT\u2019D)\n246\nUrinary Tract Infections and Sexually Transmitted Infections", "text_length": 3940, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 256/464)", "type": "chunk", "chunk_index": 255, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.599962", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.600665", "status": "complete", "chunks_added": 3}